Displaying drugs 901 - 925 of 8235 in total
Sutimlimab
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … ], a novel inhibitor of C3. ... [A245154] Notably, none of these agents are approved for use in the treatment of CAD. ... Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies …
Nonoxynol-9
Nonoxynol-9 (N-9) is a typical surfactant used as a vaginal spermicide. Spermicides are locally acting non-hormonal contraceptives. When present in the vagina during intercourse, they immobilize/inactivate/damage and/or kill sperms without eliciting systemic effects. N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams,...
Approved
Withdrawn
Lumefantrine co-artemether
Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated falciparum malaria...
Approved
Investigational
Matched Description: … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin ... Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites ... Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum …
Enmetazobactam
Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections. The combination product of enmetazobactam and cefepime was first approved by the FDA on February...
Approved
Matched Description: … on February 23, 2024, for the treatment of complicated urinary tract infections. ... [A263276]
The combination product of enmetazobactam and [cefepime] was first approved by the FDA ... broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of …
Natamycin
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Approved
Matched Description: … It is used for a variety of fungal infections, mainly topically. [PubChem] …
Povidone
Povidone, also known as polyvinylpyrrolidone (PVP) or polyvidone, is a synthetic water-soluble polymer made from the monomer N-vinylpyrrolidone used as a binder in many pharmaceutical tablets and lubricant in eye drops. It is also used in many technical applications with various roles as an adhesive, additive, and emulsifier. When in...
Approved
Withdrawn
Matched Description: … [L43942] Other formulations of povidone continue to be available. ... The FDA withdrew its approval for the use of all intravenous drug products containing povidone. ... in a few clinical studies that the application of the compound in wounds was associated with impaired …
Factor XIII (human)
Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade ... replacement of this key coagulation factor is essential for management and prevention of bleeding episodes ... the A subunit of human coagulation factor XIII. …
Sotalol
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … [A178579] It was the first of the class III anti arrhythmic drugs. ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Pantethine
Pantethine is a naturally occurring compound synthesized in the body from pantothenic acid (vitamin B5) via addition of cysteamine. It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A. Coenzyme A plays an essential role...
Approved
Investigational
Matched Description: … in the production of Coenzyme A. ... It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate ... naturally occurring compound synthesized in the body from pantothenic acid (vitamin B5) via addition of …
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. It is produced using recombinant DNA technology in CHO cell lines and...
Approved
Matched Description: … [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating …
Nomifensine
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of ... reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). ... Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic …
Secretin porcine
Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.
Approved
Matched Description: … dysfunction and the diagnosis of gastrinoma. ... Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine …
Thonzonium
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … debris and exudate, thereby promoting tissue contact of the administered medication. ... A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. ... It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular …
Durvalumab
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with ... use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of ... locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of …
Relebactam
Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Matched Description: … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination …
Faricimab
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … [A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of ... However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its ... Products for Human Use (CHMP) recommended faricimab be granted marketing authorization for the treatment of …
Tick-borne encephalitis vaccine (whole virus, inactivated)
Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus Ixodes. The disease course is variable. Some patients will be asymptomatic or experience a mild febrile illness, while others will experience the full course including neurological symptoms. TBE often manifests in a...
Approved
Matched Description: … then a second phase characterized by various neurological symptoms falling under the categorizations of ... [A237520] Due to a paucity of effective safe and effective acute therapeutic agents, vaccination remains ... recover fully following neurological TBE, neurological sequelae can last for years and rare chronic forms of …
Disopyramide
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Description: … A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac ... thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of …
Potassium citrate
Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent.
Potassium citrate is used to treat...
Approved
Investigational
Vet approved
Matched Description: … Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. ... Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis …
Dinutuximab
Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Matched Description: … It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the ... constant regions of human IgG1 heavy-chain and kappa light-chain. ... tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. …
Nefopam
Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
Approved
Investigational
Matched Description: … Nefopam has been investigated for the prevention of Kidney Transplantation. ... Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … membrane fusion step of the viral entry process, and neutralizes several RSV A and B strains. ... [L44146] It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the ... [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time …
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ... It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy …
Buclizine
Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered...
Approved
Matched Description: … attacks and in the treatment of nausea and vomiting during pregnancy. ... both antiemetic and anticholinergic effects [L6220], belonging to the _piperazine derivative_ family of ... [A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine …
Cyclizine
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Approved
Matched Description: … A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced …
Displaying drugs 901 - 925 of 8235 in total